Serum irisin concentrations were increased after transient continuous subcutaneous insulin infusion in type 2 diabetes mellitus patients.
Irisin, identified as a novel myokine, plays an important role in improving metabolic disorders, including type 2 diabetes mellitus (T2DM). In this interventional study, we investigated the alteration of serum irisin levels in T2DM subjects after transient continuous subcutaneous insulin infusion (CSII) treatment.